Hepatocyte growth factor induces gefitinib resistance of lung adenocarcinoma with epidermal growth factor receptor-activating mutations.
about
Three-dimensional lung tumor microenvironment modulates therapeutic compound responsiveness in vitro--implication for drug developmentThe discovery of hepatocyte growth factor (HGF) and its significance for cell biology, life sciences and clinical medicineUnderstanding and Targeting MET Signaling in Solid Tumors - Are We There Yet?Dysregulation of the Met pathway in non-small cell lung cancer: implications for drug targeting and resistanceThe role of MET receptor tyrosine kinase in non-small cell lung cancer and clinical development of targeted anti-MET agentsMolecular testing in lung cancer in the era of precision medicineLigand-triggered resistance to molecular targeted drugs in lung cancer: roles of hepatocyte growth factor and epidermal growth factor receptor ligandsManagement of acquired resistance to epidermal growth factor receptor kinase inhibitors in patients with advanced non-small cell lung cancerTumor heterogeneity and resistance to EGFR-targeted therapy in advanced nonsmall cell lung cancer: challenges and perspectivesStromal cells positively and negatively modulate the growth of cancer cells: stimulation via the PGE2-TNFα-IL-6 pathway and inhibition via secreted GAPDH-E-cadherin interactionMechanisms of drug resistance in kinases.Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling.Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitorsMechanisms of acquired crizotinib resistance in ALK-rearranged lung Cancers.A common BIM deletion polymorphism mediates intrinsic resistance and inferior responses to tyrosine kinase inhibitors in cancer.Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers.Discovery of a mutant-selective covalent inhibitor of EGFR that overcomes T790M-mediated resistance in NSCLC.TOPK promotes lung cancer resistance to EGFR tyrosine kinase inhibitors by phosphorylating and activating c-JunMechanisms of resistance to anti-EGFR therapy in colorectal cancerPharmacogenomics of EGFR-targeted therapies in non-small cell lung cancer: EGFR and beyondEGFR-TKI resistance in NSCLC patients: mechanisms and strategiesLoss of activating EGFR mutant gene contributes to acquired resistance to EGFR tyrosine kinase inhibitors in lung cancer cellsHedgehog pathway maintains cell survival under stress conditions, and drives drug resistance in lung adenocarcinomaDetection of hepatocyte growth factor (HGF) ligand-c-MET receptor activation in formalin-fixed paraffin embedded specimens by a novel proximity assayMET-independent lung cancer cells evading EGFR kinase inhibitors are therapeutically susceptible to BH3 mimetic agentsCetuximab and bevacizumab: preclinical data and phase II trial in recurrent or metastatic squamous cell carcinoma of the head and neck.Phase 1 dose-escalation trial evaluating the combination of the selective MET (mesenchymal-epithelial transition factor) inhibitor tivantinib (ARQ 197) plus erlotinib.Activation of the Met kinase confers acquired drug resistance in FGFR-targeted lung cancer therapy.CD200-positive cancer associated fibroblasts augment the sensitivity of Epidermal Growth Factor Receptor mutation-positive lung adenocarcinomas to EGFR Tyrosine kinase inhibitors.A phase Ib/II study of cabozantinib (XL184) with or without erlotinib in patients with non-small cell lung cancer.ERBB receptors: from oncogene discovery to basic science to mechanism-based cancer therapeutics.Dasatinib + Gefitinib, a non platinum-based combination with enhanced growth inhibitory, anti-migratory and anti-invasive potency against human ovarian cancer cells.Potential therapeutics specific to c-MET/RON receptor tyrosine kinases for molecular targeting in cancer therapy.Serum levels of hepatocyte growth factor and epiregulin are associated with the prognosis on anti-EGFR antibody treatment in KRAS wild-type metastatic colorectal cancer.The potential roles of hepatocyte growth factor (HGF)-MET pathway inhibitors in cancer treatment.Molecular mechanisms of acquired resistance to tyrosine kinase targeted therapyTKI-addicted ROS1-rearranged cells are destined to survival or death by the intensity of ROS1 kinase activity.Design and synthesis of novel Gefitinib analogues with improved anti-tumor activityEvaluation of stromal HGF immunoreactivity as a biomarker for melanoma response to RAF inhibitors.Erlotinib at a dose of 25 mg daily for non-small cell lung cancers with EGFR mutations.
P2860
Q21132280-37EC80C0-E037-42C2-ADF1-B4CADE1C4A84Q24609298-AB04C790-52CB-43B5-85B2-08A84066F3F0Q26748581-4B5F963A-5571-4895-A1D2-E2FB4393DC26Q26799900-64DC0E43-312D-4FA8-9ABD-D8FEDB470637Q26823903-F26E4BD5-557F-407D-B2A3-A618F9610A2DQ26824599-B1301DBB-E3F0-429E-A5AA-606D8752FE39Q26829104-DE91BFB3-F61E-4B54-8EFF-2C9E61225628Q26865779-FFD3E144-8563-4862-9852-C32327639395Q27014117-CDE355DC-3074-4EFE-8E6D-6A4B14A36EECQ27312218-5835BE27-0E75-4F37-8E29-BBF2D4C09A88Q27692567-7BF4E205-4645-4C93-BF8F-5DC96915273BQ27851628-02DE0277-2848-4813-B481-BE2C70F8D21BQ27851633-2BD7546B-1AD2-40F2-95E6-CDB675B0BEDBQ27851710-B3623736-130F-406E-A86A-D4FADBBC274FQ27851729-E55E9DA0-6D47-4E4B-9E27-A858641C3A36Q27852116-8B429E89-1D88-4608-ABE3-1990639048A8Q27852553-95EF6BAB-6139-4916-84B1-62A32C25DBDBQ27853317-678987F5-49FB-441C-BD61-D64A094CE506Q28074073-37C09B9F-F467-4DC7-858D-48DCF5F48832Q28080730-5AC95F20-49C5-48A3-A1D5-55C9E0F147FEQ28394310-AF6AFD93-213F-4D03-B739-14B424546C7EQ28481370-AEC3464A-7A34-46DE-B8DC-6218DC87ECF3Q28595500-984F0923-64D6-49F3-A96E-58DF692B01DDQ28743359-08145F1C-50BA-4864-B796-71CE45E348A4Q30502341-5B4ECC4D-8B39-48EE-AA3D-1EEFB62DEAC6Q30557865-0B91A152-7E27-41F8-AAB1-410EFBACB0F3Q33161299-C34EA2C3-0F07-4BD4-8807-3034C7D8EDE0Q33586758-9C0764BB-EDEE-4456-B9BA-93E6768CB124Q33587369-8856DCB6-2E24-44B2-A741-21F9E885CF4CQ33599860-6B21B8A1-DC65-4982-987B-9D5CACF7BA79Q33601653-1D6570EA-4746-4F22-9D17-22EC87984824Q33604480-95789464-E83E-404B-966F-93BA5A89C525Q33652455-B59F23E0-DE05-4264-9C73-BD2A42327417Q33682988-70D1CF7F-4132-4DF8-B2BA-6EA765DC682AQ33769429-90C2A190-175E-4630-82B4-4DCE1682E832Q33828409-7EB8AB26-D6F7-4EF5-8E2A-1CE5983166B8Q33911863-D8CC0EFF-E041-4E1E-8A33-2AFAA75FFA07Q33932286-3FA19997-FD6E-4501-88BE-F7DF82508EAEQ33935045-E261FBB9-A306-4FED-999A-E1FC9C00A502Q33945734-04A9F523-9119-4E89-B840-332BE627799A
P2860
Hepatocyte growth factor induces gefitinib resistance of lung adenocarcinoma with epidermal growth factor receptor-activating mutations.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh
2008年學術文章
@zh-hant
name
Hepatocyte growth factor induc ...... receptor-activating mutations.
@en
Hepatocyte growth factor induc ...... receptor-activating mutations.
@nl
type
label
Hepatocyte growth factor induc ...... receptor-activating mutations.
@en
Hepatocyte growth factor induc ...... receptor-activating mutations.
@nl
prefLabel
Hepatocyte growth factor induc ...... receptor-activating mutations.
@en
Hepatocyte growth factor induc ...... receptor-activating mutations.
@nl
P2093
P50
P1433
P1476
Hepatocyte growth factor induc ...... receptor-activating mutations
@en
P2093
Haruko Sakurama
Hirokazu Ogino
Hisanori Uehara
Masaki Hanibuchi
Saburo Sone
Seiji Yano
Soji Kakiuchi
Takahiro Nakamura
Toshikazu Nakamura
P304
P356
10.1158/0008-5472.CAN-08-1643
P407
P577
2008-11-01T00:00:00Z